Your browser doesn't support javascript.
loading
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.
Parri, Elina; Kuusanmäki, Heikki; Bulanova, Daria; Mustjoki, Satu; Wennerberg, Krister.
Afiliação
  • Parri E; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Kuusanmäki H; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Bulanova D; Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark; and.
  • Mustjoki S; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Wennerberg K; Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark; and.
Blood Adv ; 5(7): 1862-1875, 2021 04 13.
Article em En | MEDLINE | ID: mdl-33792631
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article